Treatments in Phase 3 Trials for FA


Omaveloxolone, or RT 408, is a small molecule Nrf2 activator that could potentially be beneficial for patients with Friedreich’s ataxia. It is being evaluated in a Phase 2/3 trial called MOXIe, for which positive top-line results of the Phase 2 portion were published in 2019.

Read more on Omaveloxolone


RT001 is an experimental fatty acid aimed at stabilizing the mitochondrial and cellular membranes against attacks and restores cellular health. It is being tested in Friedreich’s ataxia patients in a Phase 3 trial, which began in October 2019.

Read more on RT001
Books icon

Your FA Community

Visit the Friedreich’s Ataxia News forums to connect with others in the FA community to discuss issues, ask questions, and share your experiences related to scientific research and clinical trials.

View the topic
Speech bubble icon